Last reviewed · How we verify
CTM Boost
CTM Boost is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
CTM Boost is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | CTM Boost |
|---|---|
| Sponsor | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting SGLT2, CTM Boost reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This results in improved glycemic control and weight loss in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy (NA)
- Connective Tissue Matrix for Rotator Cuff Tendinopathy (PHASE4)
- Efficacy of CTM for Tennis ELbow (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: